Lucira Health, Inc. (LHDXQ)
| Market Cap | 18.36M |
| Revenue (ttm) | 212.13M |
| Net Income (ttm) | -143.28M |
| Shares Out | n/a |
| EPS (ttm) | -3.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,317 |
| Open | 0.545 |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 3.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About LHDXQ
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and ... [Read more]
Financial Performance
In 2021, Lucira Health's revenue was $93.06 million, an increase of 34492.94% compared to the previous year's $269,000. Losses were -$64.83 million, 73.6% more than in 2020.
Financial StatementsNews
Why Is Lucira Health (LHDX) Stock Down 14% Today?
Lucira Health (NASDAQ: LHDX) stock is falling on Friday after the company's shares have seen extreme volatility throughout the week. That includes a massive rally earlier this week that saw the compa...
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test...
Why Is Lucira Health (LHDX) Stock Up 237% Today?
Lucira Health (NASDAQ: LHDX) stock is rocketing higher on Monday thanks to an update from the FDA. The big news here is Lucira Health getting FDA approval for its at-home Covid-19 and flu combination...
Lucira stock more than doubles after hours on FDA OK for COVID-19, flu test
Lucira Health Inc. LHDX, +13.45% shares more than doubled in the extended session Friday after the Food and Drug Administration authorized use of its at-home test that can detect both the flu and the ...
Why Is Lucira Health (LHDX) Stock Down 34% Today?
Lucira Health (NASDAQ: LHDX) stock is taking a beating on Thursday after the company filed for Chapter 11 bankruptcy protection. To go along with that filing, Lucira Health says it intends to sell it...
Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
No debtor-in-possession financing required as the Company intends to fund operations and the sale process with available cash on hand. No debtor-in-possession financing required as the Company intends...
5 Big Winners as Wall Street Wraps Up Strong January Gains
AppHarvest (APPH), Lucira Health (LHDX), Lucid Group (LCID), Life Time Group (LTH) & Ameriprise Financial (AMP) not only have made the most of the January rally but also are poised to gain further thi...
Lucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in Canada
EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, today announced the Canadian launch of Lucira Conn...
Why Lucira Health (LHDX) Stock Up 400% Today?
One of the biggest upside movers in today's upside-down market is medical technology company Lucira Health (NASDAQ: LHDX). This little-known maker of PCR tests for various infectious diseases is on a...
Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test
With 99% accuracy and within 30 minutes, institutions will simultaneously and accurately test residents, health workers and visitors for COVID-19 and Flu A/B With 99% accuracy and within 30 minutes, i...
Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care
PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season PCR-Quality Accuracy with Results in 30 Minutes or Less, Just in Time for Flu Season
Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX) today announced the launch of Lucira Connect, a new virtual care program that all...
Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and comme...
Lucira Health to Announce Third Quarter 2022 Financial Results
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative...
Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays
Study Reveals Lucira's Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexually Transmitted Infections Study Reveals Lucira's Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexu...
Lucira Health to Participate in LifeSci Partners HealthTech Symposium
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformativ...
Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative...
Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and comme...
Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test
EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and comme...
Lucira Health to Announce Second Quarter 2022 Financial Results
EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative...
Lucira Health Announces First Quarter 2022 Results and Business Update
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commer...
Lucira Health files for FDA authorization of first COVID-19 & flu at-home molecular test
Lucira Health Inc. LHDX, -6.02% said Thursday it has filed for Food and Drug Administration authorization for its first-of-its-kind COVID-19 & flu at-home molecular test. The medical tech company, whi...
Lucira Files for Authorization of First-of-its-Kind COVID-19 & Flu At-Home Molecular Test
This first ever at-home COVID-19 and flu test is designed to allow individuals to differentiate between the infections and seek appropriate treatment within 30 minutes from home This first ever at-hom...
Lucira Health to Participate in Bank of America 2022 Healthcare Conference
EMERYVILLE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative ...
Lucira Health to Announce First Quarter 2022 Financial Results
EMERYVILLE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformativ...